Welcome!

News Feed Item

2013 Japanese Hospital Microbiology Testing Market

NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

2013 Japanese Hospital Microbiology Testing Market

http://www.reportlinker.com/p01083065/2013-Japanese-Hospital-Microbiolog...

This new report from Venture Planning Group contains 891 pages, 75 tables, and presents a comprehensive analysis of the Japanese hospital microbiology testing market, including:

·         Major issues pertaining to the Japanese hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

·         Current scientific views on definition, epidemiology, and etiology of major infectious diseases and microorganisms.

·         Volume and sales forecasts for 80 microbiology tests performed in Japanese hospital laboratories.

·         Instrumentation technologies and feature comparison of leading analyzers.

·         Sales and market shares of leading suppliers.

·         Emerging diagnostic technologies and their potential market applications.

·         Product development opportunities.

·         Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

·         Business opportunities and strategic recommendations for suppliers.

Contains 891 pages and 75 tables

 

 

 

Table of Contents

 

Introduction

Worldwide Market and Technology Overview

A. Major Infectious Disease Tests

1. AIDS

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

2. Adenovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

d. Adeno-Associated Viruses(AAV)

3. Aeromonas

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

4. Anthrax/Bacillus Anthracis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

5. Arboviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

6. Babesiosis

a. Background

7. Bacillary Epithelioid Angiomatosis (BEA)

And Other Bartonella (Rochalimaea)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

8. Blastocystis Hominis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

9. Brucella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

10. Campylobacter

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

11. Candida

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

12. Chagas Disease

a. Background

13. Chancroid

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

14. Chlamydia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

15. Clostridium Difficile

a. Background

b. Diagnostic Tests

c. Drugs and Vaccines

16. Coronaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

17. Coxsackieviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

18. Creutzfeldt-Jakob's Disease

a. Background

b. Diagnostic Tests

c. Vaccines

19. Cryptosporidium Parvum

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

20. Cyclospora Cayetanensis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

21. Cytomegalovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

22. Ebola Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

23. E. Coli

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

24. EchoVirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

25. Encephalitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

26. Enteroviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

27. Epstein-Barr Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

28. Giardia Lamblia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

29. Gonorrhea

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

30. Granuloma Inguinale

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

31. Hantavirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

32. Helicobacter Pylori

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

33. Hepatitis

a. Background

b. Hepatitis A

c. Hepatitis B

d. Hepatitis C

e. Vaccines and Drugs

34. Herpes Simplex Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

36. Influenza Viruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

37. Legionella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

38. Lyme Disease

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

39. Lymphogranuloma Venereum (LGV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

40. Malaria

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

41. Measles (Rubeola)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

42. Meningitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

43. Microsporidium

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

44. Mononucleosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

45. Mumps

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

46. Mycoplasma

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

47. Papillomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

48. Parvovirus B19

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

49. Pneumonia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

50. Polyomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

51. Pseudomonas Aeruginosa

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

52. Rabies

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

54. RhinoViruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

55. RotaVirus (REOVIRUS)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

56. Rubella(MEASLES)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

57. Salmonellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

58. Septicemia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

59. Shigellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

60. Staphylococcus Aureus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

61. Streptococci

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

62. Syphilis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

63. Toxoplasmosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

64. Trichomonas Vaginalis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

65. Tuberculosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

66. Vibrio

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

67. West Nile Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

68. Yersina

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

B. Instrumentation Review of Leading Analyzers Marketed

by Abbott, Beckman Coulter/Danaher, BioMerieux,

Ortho-Clinical Diagnostics, Roche, Siemens, Tosoh,

Wallac and Other Suppliers

C. Emerging Diagnostic Technologies

1. Molecular Diagnostics

2. Monoclonal Antibodies

3. Immunoassays

4. Differential Light Scattering

5. Information Technology

6. Artificial Intelligence

7. Liposomes

8. Flow Cytometry

9. Chromatography

10. Diagnostic Imaging

11. Gel Microdroplets

12. Other

Japan

A. Executive Summary

B. Business Environment

C. Market Structure

D. Market Size, Growth and Major Suppliers

Major Product Development Opportunities

A. Instrumentation

B. Reagent Kits and Test Systems/Panels

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies for Decentralized

Testing Markets

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Assessments

- Abbott

- Affymetrix

- Beckman Coulter/Danaher

- Becton Dickinson

- bioMerieux

- Bio-Rad

- Cepheid

- Diamedix

- DiaSorin

- Eiken Chemical

- Enzo Biochem

- Fujirebio

- Gen-Probe

- Hologic

- ID Biomedical

- Innogenetics/Solvay

- Kreatech

- Life Technology

- Lonza

- Nanogen/Elitech

- Novartis Diagnostics

- Ortho-Clinical Diagnostics

- Qiagen

- Roche

- Scienion

- Sequenom

- SeraCare

- Siemens

- Takara Bio

- Thermo Fisher

- Wallac

- Wako

 

 

 

List of Tables

 

Major Companies Developing or Marketing AIDS Tests

Major Companies Developing or Marketing Adenovirus

Tests

Major Companies Developing or Marketing Bartonella

Tests

Major Companies Developing or Marketing

Campylobacter Tests

Major Companies Developing or Marketing Candida

Tests

Major Companies Developing or Marketing Chlamydia

Tests

Major Companies Developing or Marketing Clostridium

Tests

Major Companies Developing or Marketing Coronavirus

Tests

Major Companies Developing or Marketing Cryptosporidium

Tests

Major Companies Developing or Marketing CMV Tests

Major Companies Developing or Marketing Echovirus

Tests

Major Companies Developing or Marketing Enterovirus

Tests

Major Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing Giardia

Tests

Major Companies Developing or Marketing Gonorrhea

Tests

Major Companies Developing or Marketing Hantavirus

Tests

Major Companies Developing or Marketing Helicobacter

Pylori Tests

Major Companies Developing or Marketing Hepatitis

Tests

Major Companies Developing or Marketing Herpes

Tests

Major Companies Developing or Marketing Influenza

Tests

Major Companies Developing or Marketing Legionella

Tests

Major Companies Developing or Marketing Lyme Disease

Tests

Major Companies Developing or Marketing Lymphogranuloma

Tests

Major Companies Developing or Marketing Malaria

Tests

Major Companies Developing or Marketing Measles

Tests

Major Companies Developing or Marketing Meningitis

Tests

Major Companies Developing or Marketing Microsporidium

Tests

Major Companies Developing or Marketing

Mononucleosis Tests

Major Companies Developing or Marketing Mumps Tests

Major Companies Developing or Marketing Mycoplasma

Tests

Major Companies Developing or Marketing Papilloma

Virus Tests

Major Companies Developing or Marketing Parvovirus

Tests

Major Companies Developing or Marketing Pneumonia

Tests

Major Companies Developing or Marketing RSV Tests

Major Companies Developing or Marketing Rotavirus

Tests

Major Companies Developing or Marketing Rubella

Tests

Major Companies Developing or Marketing Salmonella

Tests

Major Companies Developing or Marketing Septicemia

Tests

Major Companies Developing or Marketing Shigella

Tests

Major Companies Developing or Marketing Staphylococci

Tests

Major Companies Developing or Marketing

Streptococci Tests

Major Companies Developing or Marketing Syphilis

Tests

Major Companies Developing or Marketing Toxoplasmosis

Tests

Major Companies Developing or Marketing Trichomonas

Tests

Major Companies Developing or Marketing Tuberculosis

Tests

Major Companies Developing or Marketing West Nile

Tests

Major Companies Developing or Marketing Yersinia Tests

Japan Summary Table

All Infectious Diseases Test Volume and Diagnostics

Sales Forecast by Market Segment

Japan

Hospital Laboratories Performing Infectious Disease

Tests by Bed Size

Japan

Hospital Laboratories Infectious Disease Test

Volume Forecast

Japan

Hospital Laboratories Infectious Disease Diagnostics

Market Forecast

Japan

AIDS Testing Market Diagnostics Sales

by Major Supplier

Japan

Campylobacter Testing Market Diagnostics Sales

by Major Supplier

Japan

Candida Testing Market Diagnostics Sales

by Major Supplier

Japan

Chlamydia Testing Market Diagnostics Sales

by Major Supplier

Japan

CMV Testing Market Diagnostics Sales

by Major Supplier

Japan

Gonorrhea Testing Market Diagnostics Sales

by Major Supplier

Japan

Hepatitis Testing Market Diagnostics Sales

by Major Supplier

Japan

Hepatitis C Testing Market Diagnostics Sales

by Major Supplier

Japan

Herpes Testing Market Diagnostics Sales

by Major Supplier

Japan

Legionella Testing Market Diagnostics Sales Forecast

by Major Supplier

Japan

Meningitis Testing Market Diagnostics Sales

by Major Supplier

Japan

Mononucleosis Testing Market Diagnostics Sales

by Major Supplier

Japan

Mycoplasma Testing Market Diagnostics Sales

by Major Supplier

Japan

Pneumonia Testing Market Diagnostics Sales

by Major Supplier

Japan

RSV Testing Market Diagnostics Sales by Major Supplier

Japan

Rotavirus Testing Market Diagnostics Sales

by Major Supplier

Japan

Rubella Testing Market Diagnostics Sales

by Major Supplier

Japan

Septicemia Testing Market Diagnostics Sales

by Major Supplier

Japan

Shigella Testing Market Diagnostics Sales

by Major Supplier

Japan

Streptococci Testing Market Diagnostics Sales

by Major Supplier

Japan

Syphilis Testing Market Diagnostics Sales

by Major Supplier

Japan

Toxoplasmosis Testing Market Diagnostics Sales

by Major Supplier

Japan

Trichomonas Testing Market Diagnostics Sales

by Major Supplier

Japan

Tuberculosis Testing Market Diagnostics Sales

by Major Supplier

 

 

 

To order this report:

In_Vitro_Diagnostic Industry: 2013 Japanese Hospital Microbiology Testing Market

 

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Transforming cloud-based data into a reportable format can be a very expensive, time-intensive and complex operation. As a SaaS platform with more than 30 million global users, Cornerstone OnDemand’s challenge was to create a scalable solution that would improve the time it took customers to access their user data. Our Real-Time Data Warehouse (RTDW) process vastly reduced data time-to-availability from 24 hours to just 10 minutes. In his session at 21st Cloud Expo, Mark Goldin, Chief Technolo...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
In the fast-paced advances and popularity in cloud technology, one of the most critical factors revolves around concerns for security of your critical data. How to assure both your company and your customers they can confidently trust and utilize your cloud environment is most often top on the list. There is a method to evaluating and providing security that exceeds conventional modes of protecting data both within the cloud as well externally on mobile and other devices. With the public failure...